A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT06600321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Study identification
- NCT ID
- NCT06600321
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 158 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2024
- Primary completion
- Sep 29, 2027
- Completion
- Oct 30, 2027
- Last update posted
- Jun 16, 2026
2024 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Trial Site | Phoenix | Arizona | 85054 | Recruiting |
| Clinical Trial Site | La Jolla | California | 92037 | Recruiting |
| Clinical Trial Site | Los Angeles | California | 90033 | Recruiting |
| Clinical Trial Site | Jacksonville | Florida | 32224 | Recruiting |
| Clinical Trial Site | Atlanta | Georgia | 30322 | Recruiting |
| Clinical Trial Site | Chicago | Illinois | 60637 | Recruiting |
| Clinical Trial Site | Ann Arbor | Michigan | 48109 | Recruiting |
| Clinical Trial Site | Rochester | Minnesota | 55905 | Recruiting |
| Clinical Trial Site | New York | New York | 10029 | Recruiting |
| Clinical Trial Site | New York | New York | 10032 | Completed |
| Clinical Trial Site | Cleveland | Ohio | 44106 | Recruiting |
| Clinical Trial Site | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Clinical Trial Site | Dallas | Texas | 75390 | Recruiting |
| Clinical Trial Site | Houston | Texas | 77030 | Recruiting |
| Clinical Trial Site | San Antonio | Texas | 78229 | Recruiting |
| Clinical Trial Site | Richmond | Virginia | 23298 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06600321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 16, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06600321 live on ClinicalTrials.gov.